Company news
Protara Therapeutics, Inc. (NASDAQ:TARA) news
Protara Therapeutics, Inc. news releases on 6ix. Latest, Sep 3, 2024: Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment…
Press releases — page 2
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 2, 2024
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
August 5, 2024
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 23, 2024
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
May 20, 2024
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
May 1, 2024
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
April 4, 2024
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
April 4, 2024
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
April 4, 2024
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 12, 2024
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
November 29, 2023
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
November 2, 2023
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
October 22, 2023
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
September 19, 2023
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 4, 2023
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
August 2, 2023
Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ
May 14, 2023
Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update
May 3, 2023
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
May 1, 2023
Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development
April 27, 2023
Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 7, 2023
Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
February 1, 2023
Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer
January 29, 2023
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
November 30, 2022
Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview
November 2, 2022
Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022
Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview
August 8, 2022
Protara Therapeutics Announces Departure of Chief Financial Officer
June 20, 2022
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting
May 25, 2022
Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022
Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
May 11, 2022
Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview
May 4, 2022
Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer
March 23, 2022
Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview
March 8, 2022
Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference
January 31, 2022
Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer
January 9, 2022
Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
January 3, 2022
Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview
November 3, 2021
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
October 11, 2021
Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 16, 2021
Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition
September 12, 2021
Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 6, 2021
Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview
August 4, 2021
Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
July 6, 2021
Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors
June 9, 2021
Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences
May 12, 2021
Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview
May 5, 2021
Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations
April 22, 2021
Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer
April 18, 2021
Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview
March 10, 2021